Accupril: Effective Blood Pressure Control for Cardiovascular Health
Accupril
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | 1.33 $ | 79.56 $ (0%) | 🛒 Add to cart |
| 90 | 1.08 $ | 119.34 $ 97.11 $ (19%) | 🛒 Add to cart |
| 120 | 0.99 $ | 159.12 $ 119.34 $ (25%) | 🛒 Add to cart |
| 180 | 0.94 $ | 238.68 $ 168.48 $ (29%) | 🛒 Add to cart |
| 270 | 0.88 $ | 358.02 $ 237.51 $ (34%) | 🛒 Add to cart |
| 360 | 0.83 $
Best per pill | 477.36 $ 299.52 $ (37%) | 🛒 Add to cart |
Accupril (quinapril hydrochloride) is an angiotensin-converting enzyme (ACE) inhibitor prescription medication designed for the management of hypertension and heart failure. It works by relaxing blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently. This medication is a cornerstone in cardiovascular therapy, offering proven efficacy in reducing blood pressure and improving cardiac outcomes in appropriate patient populations. Proper diagnosis and ongoing medical supervision are essential for safe and effective treatment.
Features
- Active ingredient: Quinapril hydrochloride
- Drug class: Angiotensin-converting enzyme (ACE) inhibitor
- Available in tablet formulations: 5 mg, 10 mg, 20 mg, 40 mg
- Oral administration, typically once or twice daily
- Bioavailability approximately 60%
- Peak plasma concentration reached within 1 hour
- Half-life of approximately 2 hours (quinapril) and 3 hours (active metabolite quinaprilat)
- Primarily renal excretion
- Manufactured under strict pharmaceutical quality standards
Benefits
- Effectively lowers elevated blood pressure, reducing strain on the cardiovascular system
- Improves survival rates in patients with congestive heart failure when used as part of comprehensive therapy
- Demonstrates renal protective effects in hypertensive patients with diabetes
- Reduces afterload on the heart, improving cardiac output in heart failure patients
- Shows proven efficacy in combination with other antihypertensive agents when needed
- Provides 24-hour blood pressure control with appropriate dosing
Common use
Accupril is primarily indicated for the treatment of hypertension, either as monotherapy or in combination with thiazide diuretics. It is also approved for the management of heart failure as adjunctive therapy when standard treatment requires additional support. In clinical practice, it may be used off-label for certain renal protective indications in diabetic patients, though this requires careful specialist evaluation. The medication is typically prescribed as part of a comprehensive cardiovascular risk reduction strategy that may include lifestyle modifications and other pharmacological interventions.
Dosage and direction
Dosage must be individualized based on therapeutic response and patient tolerance. For hypertension: Initial dose is typically 10-20 mg once daily, which may be adjusted to 20-80 mg daily divided into one or two doses. For heart failure: Therapy is usually initiated at 5 mg twice daily, which may be increased as tolerated to target doses of 20-40 mg daily in two divided doses. Patients taking diuretics should have them discontinued 2-3 days before starting Accupril to reduce the risk of symptomatic hypotension. Dosage adjustments are necessary in renal impairment: For creatinine clearance >60 mL/min, usual dose; 30-60 mL/min, reduce initial dose by 50%; 10-30 mL/min, reduce initial dose by 75%. Tablets should be swallowed whole with water, with or without food, though consistency in administration relative to meals is recommended.
Precautions
Patients should be monitored for hypotension, especially during initial dosing and titration periods. Renal function and serum potassium should be assessed before and during treatment. Angioedema may occur at any time during therapy, requiring immediate medical attention. Use with caution in patients with collagen vascular disease, renal artery stenosis, or pre-existing renal impairment. Neutropenia/agranulocytosis has been reported with ACE inhibitors, particularly in patients with renal impairment or connective tissue diseases. Hyperkalemia may occur, particularly in patients with renal insufficiency or diabetes, or those taking potassium-sparing diuretics or potassium supplements. Cough may develop and typically resolves after discontinuation of therapy.
Contraindications
Accupril is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment. It is also contraindicated in patients with hereditary or idiopathic angioedema. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes. The medication is contraindicated during the second and third trimesters of pregnancy due to potential fetal harm. Hypersensitivity to quinapril or any component of the formulation, or cross-hypersensitivity to other ACE inhibitors, represents an absolute contraindication.
Possible side effect
Common adverse reactions include headache (approximately 6-14%), dizziness (4-11%), fatigue (2-6%), and cough (2-4%). Less frequent side effects may include gastrointestinal disturbances such as nausea (2-3%) and abdominal pain (1-2%). Orthostatic hypotension occurs in approximately 1-2% of patients. Rare but serious adverse effects include angioedema (0.1-0.5%), neutropenia/agranulocytosis, hepatic failure, and pancreatitis. Renal impairment, including acute renal failure, may occur particularly in volume-depleted patients or those with renal artery stenosis. Hyperkalemia has been reported in approximately 2% of patients.
Drug interaction
Concomitant use with diuretics may potentiate hypotensive effects. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect and increase renal impairment risk. Lithium levels may increase with concomitant ACE inhibitor use, requiring monitoring. Dual blockade of the renin-angiotensin system with ARBs, aliskiren, or other ACE inhibitors increases risks of hypotension, hyperkalemia, and renal impairment. Antidiabetic agents may see enhanced hypoglycemic effects. Gold injections may cause nitritoid reactions.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is near the time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed dose. Consistency in dosing is important for maintaining stable blood pressure control, so patients should establish routines to support regular administration. If multiple doses are missed, blood pressure should be monitored and the prescribing physician consulted for guidance.
Overdose
The most likely manifestation of overdose is hypotension, which may be severe. Other potential effects include bradycardia, circulatory shock, electrolyte disturbances, and renal failure. Supportive measures should be implemented, including volume expansion with normal saline to restore blood pressure. Removal of quinapril and its metabolites by hemodialysis may be effective. Bradycardia may require atropine administration. Monitoring should include continuous ECG, blood pressure, and renal function assessment. The patient should be managed in an intensive care setting with appropriate hemodynamic monitoring capabilities.
Storage
Accupril tablets should be stored at controlled room temperature between 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F). The medication should be kept in its original container, tightly closed, and protected from light and moisture. Tablets should not be stored in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use tablets that show signs of discoloration, crumbling, or other physical deterioration. Proper disposal of expired or unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Accupril is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual patient responses may vary, and therapeutic decisions should be based on professional medical judgment considering the patient’s complete medical profile. The prescribing physician should be consulted for specific medical advice, diagnosis, and treatment recommendations. Full prescribing information including boxed warnings should be reviewed before initiation of therapy.
Reviews
Clinical studies demonstrate Accupril’s efficacy in reducing systolic and diastolic blood pressure by approximately 10-15 mmHg and 5-10 mmHg respectively in hypertensive patients. In heart failure trials, it has shown significant improvement in exercise tolerance and reduction in mortality rates. Many patients report satisfactory blood pressure control with once-daily dosing, though individual responses vary. Some patients note the development of dry cough as a limiting factor, while others tolerate the medication well long-term. The medication generally receives positive evaluation in clinical practice for its efficacy profile and generally favorable side effect spectrum compared to other antihypertensive classes.